A detailed history of Core Cap Advisors, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 330 shares of EDIT stock, worth $805. This represents 0.0% of its overall portfolio holdings.

Number of Shares
330
Previous 500 34.0%
Holding current value
$805
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$3.39 - $5.96 $576 - $1,013
-170 Reduced 34.0%
330 $1,000
Q2 2024

Aug 08, 2024

BUY
$4.67 - $7.28 $2,335 - $3,640
500 New
500 $2,000
Q4 2022

Feb 10, 2023

BUY
$8.32 - $13.21 $607 - $964
73 New
73 $0
Q2 2022

Aug 11, 2022

BUY
$9.99 - $21.35 $729 - $1,558
73 New
73 $1,000
Q1 2022

Apr 29, 2022

SELL
$14.08 - $27.63 $1,027 - $2,016
-73 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$26.55 - $40.57 $1,938 - $2,961
73 New
73 $2,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.